Khang & Khang LLP announces that it is investigating claims of potential
misrepresentations by Vital Therapies, Inc. (“Vital” or the
“Company”) (NASDAQ: VTL).
The investigation focuses on whether the Company and its officers
violated securities laws by issuing misleading information to investors.
If you purchased shares of Vital during the Class Period, please contact
Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd
Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until certification
occurs, you are not represented by an attorney. You may choose to take
no action and remain a passive class member.
The investigation concerns whether the Company issued materially false
and misleading statements to investors and/or failed to disclose
material information regarding Vital Therapies’ ELAD System studies,
VTI-208, VTI-210, and VTI-212, including: (1) the studies’ independent
significance; (2) the degree to which the studies were interrelated; and
(3) that in the case of the failure of the VTI-208 trial, Vital
Therapies would not continue the VTI-210 trial.
If you wish to learn more about this lawsuit, or if you have any
questions concerning this notice or your rights, please contact Joon M.
Khang, a prominent litigator for almost two decades, by telephone: (949)
419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151217006626/en/
Copyright Business Wire 2015